Person: DELİGÖNÜL, ADEM
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DELİGÖNÜL
First Name
ADEM
Name
25 results
Search Results
Now showing 1 - 10 of 25
Publication Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triplenegative breast cancer(Termedia Publishing House Ltd, 2014-01-01) Çubukçu, Erdem; Ölmez, Ömer Fatih; Kanat, Özkan; Kabul, Selva; Canhoroz, Mustafa; Avcı, Nilüfer; Hartavi, Mustafa; Deligönül, Adem; Çubukçu, Sinem; Manavoğlu, Osman; ÇUBUKÇU, ERDEM; Ölmez, Ömer Fatih; Kanat, Özkan; KABUL, SELVA; Canhoroz, Mustafa; Avcı, Nilüfer; Hartavi, Mustafa; DELİGÖNÜL, ADEM; ÇUBUKÇU, SİNEM; Manavoğlu, Osman; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; ETP-1691-2022; DJG-4827-2022; CYM-0930-2022; CAH-9737-2022; CJW-6018-2022; CCT-7946-2022; CUI-5353-2022; ESM-4544-2022; JJB-0254-2023; FLP-9613-2022Introduction: Triple-negative breast cancers (TNBCs) -which lack the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2)-have no established markers that can be used for prognostic stratification. As adiponectin has been previously implicated in a more aggressive phenotype of primary breast cancer, we explored the relation between adiponectin immunohistochemical expression and prognosis in TNBCs.Material and methods: Immunohistochemical staining for adiponectin was performed in 38 TNBC patients. Disease-free survival (DFS) and overall survival (OS) served as the main outcome measures.Results: Of the 38 TNBC patients, 18 (47%) had negative and 20 (53%) positive adiponectin immunohistochemical expression. We did not find any significant association between adipo-nectin immunohistochemical expression and the baseline characteristics. In addition, there were no associations between adiponectin immunohistochemical expression and prognosis.Conclusions: Although our results suggest that adiponectin immunohistochemical expression is not of prognostic significance in TNBCs, further studies are warranted to determine the role of this adipokine in breast cancer biology.Publication DPYD c.1905+1G>A promotes fluoropyrimidine-induced anemia, a prognostic factor in disease-free survival, in colorectal cancer(Mary Ann Liebert, Inc, 2021-04-01) Deligönül, Adem; Aksoy, Seçil; Tezcan, Gülçin; Tunca, Berrin; Kanat, Özkan; Çubukcu, Erdem; Yılmazlar, Tuncay; Öztürk, Ersin; Egeli, Ünal; Çeçener, Gülşah; Alemdar, Adem; Evrensel, Türkkan; DELİGÖNÜL, ADEM; AKSOY, SEÇİL; TEZCAN, GÜLÇİN; TUNCA, BERRİN; Kanat, Özka; ÇUBUKÇU, ERDEM; YILMAZLAR, AHMET TUNCAY; EGELİ, ÜNAL; ÇEÇENER, GÜLŞAH; ALEMDAR, ADEM; EVRENSEL, TÜRKKAN; Sağlık Bilimleri Enstitüsü; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0002-6400-4911; 0000-0002-5956-8755; 0000-0002-1619-6680; 0000-0001-8593-5101; 0000-0001-7904-883X; 0000-0002-3820-424X; HIZ-7332-2022; AAH-1420-2021; AAH-3843-2020; ESM-4544-2022; JDG-0330-2023; ABI-6078-2020; CYM-0930-2022; ETP-1691-2022; CKK-3621-2022; AAP-9988-2020; EXZ-0745-2022Background and Aim: In 10-30% of colorectal cancer (CRC) patients, toxic reactions occur after fluoropyrimidine-based chemotherapy. A dihydropyridine dehydrogenase (DPYD) gene variant, c.1905 + 1G>A, leads to intolerance to fluoropyrimidines. Due to the low frequency of this variant in many populations, the prevalence of fluoropyrimidine-induced hematologic side effects in CRC patients with the c.1905 + 1G>A variant is unclear. In this study, we investigated the prevalence of the DPYD c.1905 + 1 variants in a Turkish CRC cohort and the potential effects of these variants on fluoropyrimidine-induced hematologic side effects.Materials and Methods: The DPYD c.1905 + 1 variant was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis and confirmed by Sanger sequencing in peripheral blood samples of 100 CRC patients who received fluoropyrimidine-based chemotherapy and 60 healthy volunteers. The association of c.1905 + 1 variants with susceptibility to hematologic side effects was evaluated.Results: The DPYD c.1905 + 1G>A variant was more common in the CRC group than in the healthy control group (p = 0.001). The presence of the c.1905 + 1G>A variant was associated with thrombocytopenia (p = 0.039) and anemia (p = 0.035). CRC patients with fluoropyrimidine-induced anemia had shorter disease-free survival than CRC patients without fluoropyrimidine-induced anemia (p = 0.0009).Conclusions: Before administering fluoropyrimidine-based chemotherapy, genetic screening for the DPYD c.1905 + 1G>A variant should be performed with the aim of preventing anemia and anemia-induced complications in CRC patients.Publication Retrospective comparison of the efficacy of therapeutic agents in metastatic soft-tissue sarcomas(Kare Yayınevi, 2023-03-02) Caner, Burcu; Ocak, Birol; Şahin, Ahmet Bilgehan; Salı, Seda; Çoban, Eyüp; Deligönul, Adem; Çubukçu, Erdem; Evrensel, Türkkan; CANER, BURCU; SALİ, SEDA; ÇOBAN, EYÜP; DELİGÖNÜL, ADEM; ÇUBUKÇU, ERDEM; EVRENSEL, TÜRKKAN; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0003-1591-3323 ; HJH-6371-2023; DPO-3759-2022; JIS-1916-2023; JHC-1731-2023; JGT-4101-2023; EXZ-0745-2022OBJECTIVEThere are few agents used in soft-tissue sarcoma treatment. We compared the efficacy of therapies, aiming to identify the best therapy sequence, and reveal the factors affecting the risk of progression or death.METHODSFifty-five patients were included in the study. Data such as age, gender, tumor primary site, histological type, tumor grade, the Ki67 percentage score, treatments, radiotherapy, and metastasectomy history, the dates of diagnosis, metastasis, progression, and death were retrospectively evaluated. Progression-free survival (PFS) and overall survival (OS) for therapies, and the risk factors for the progression or death were analyzed.RESULTSIn the first-line, gemcitabine-docetaxel provided longer PFS than the doxorubicin-ifosfamide combination (7.4 months vs. 4.8 months, p=0.035), although this did not result in OS difference. In the second line, the efficacy of trabectedin and pazopanib were similar, whereas trabectedin showed less activity in liposarcomas. In the third-line and beyond, trabectedin, pazopanib and eribulin showed similar PFS and OS. The only factor that affected the risk of death was metastasectomy (HR for death: 0.35, 95% CI: 0.18-0.66, p=0.001). CONCLUSIONWe found that agents used in soft-tissue sarcoma have similar efficacy, which is not affected by the previous therapies. However, it should be noted that soft-tissue sarcomas include many histological types, and to choose the optimal drug, the histological type must be one of the major factors considered. Furthermore, all patients should be evaluated for possible metastasectomy, which came out as the only factor reducing the risk of death in our study.Publication The immunohistochemical expression of c-met is an independent predictor of survival in patients with glioblastoma multiforme(Springer International Publishing Ag, 2014-02-01) Ölmez, O. F.; Çubukçu, E.; ÇUBUKÇU, ERDEM; Evrensel, T.; EVRENSEL, TÜRKKAN; Kurt, M.; Avcı, N.; Tolunay, S.; TOLUNAY, ŞAHSİNE; Bekar, Ahmet; BEKAR, AHMET; Deligönül, Adem; DELİGÖNÜL, ADEM; Hartavi, M.; Alkış, N.; Manavoğlu, O.; Tıp Fakültesi; Onkoloji Ana Bilim Dalı; ABX-9081-2022; AAJ-1027-2021; AAA-3961-2020; AAI-1612-2021Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols.Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 +/- A 12.9 years, age range: 23-81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures.Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 +/- A 2.3 vs. 22.6 +/- A 2.5 months, respectively, p < 0.01) and PFS (12.3 +/- A 2.1 vs. 19.1 +/- A 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2-1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1-2.3, p < 0.05).Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care.Publication Major and minor salivary gland cancers: A multicenter retrospective study(Wiley, 2023-04-21) Hacioglu, Muhammet Bekir; Erdogan, Bulent; Bardakci, Murat; Algin, Efnan; Gulbagci, Burcu; Hacibekiroglu, Ilhan; Hamdard, Jamshid; Ölmez, Ömer Fatih; Akkus, Hadi; Öksuzoglu, Berna; Goksu, Sema Sezgin; Dae, Shute Ailia; Sumbul, Ahmet Taner; Ugrakli, Muzaffer; Karaagac, Mustafa; Sahin, Elif; Çabuk, Devrim; Özer, Özden; Yavuzsen, Tugba; Arikan, Rukiye; Kostek, Osman; Atci, Muhammed Mustafa; Sakin, Abdullah; Deligönül, Adem; Bayir, Duygu; Dincer, Murat; Ünsal, Oktay; Yazici, Ozan; Zeynelgil, Esra; Gulmez, Ahmet; Harputluoglu, Hakan; Erol, Cihan; Sendur, Mehmet Ali Nahit; Aytekin, Aydin; Akagunduz, Baran; Öner, İrem; Er, Özlem; Öztosun, Bugra; Gumus, Mahmut; Biricik, Fatih Selçuk; Aykan, Musa Bariş; Karadurmus, Nuri; Degerli, Ezgi; Demirci, Nebi Serkan; Turkmen, Esma; Sakalar, Teoman; Secmeler, Şaban; Tanriverdi, Özgur; Alkan, Ali; Kemal, Yasemin; Çil, İbrahim; Ünal, Çaglar; Iriagac, Yakup; Alan, Çzkan; Balli, Sevinç; Ürun, Yuksel; Özcan, Erkan; Turhal, Nazim Serdar; Cicin, İrfan; DELİGÖNÜL, ADEM; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; ESM-4544-2022BackgroundMost of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. MethodsA total of 37 medical oncology clinics from different regions of Turkey participated in this retrospective-multicenter study. The analyzed data included clinical and demographical features, primary treatment, metastasis localizations, and treatments and includes certain pathologic features. ResultsThe study included data from a total of 443 SGCs. 56.7% was in major salivary glands and 43.3% was in minor salivary glands. Distant metastasis in the major SGCs was statistically significantly more common than in the minor SGCs, locoregional recurrence was statistically significantly more common in the minor SGCs than in the major SGCs (p = 0.003). ConclusionsEpidemiological information, metastasis and recurrence patterns, treatment modalities, and survival analysis of the patients over 20 years of follow-up are presented.Publication Liver metastasis of breast carcinoma: An unusual presentation and growth pattern(Wolters Kluwer Medknow Publications, 2023-10-01) Özsen, Mine; ÖZŞEN, MİNE; Ugraş, Nesrin; UĞRAŞ, NESRİN; Deligönül, Adem; DELİGÖNÜL, ADEM; Yerci, Ömer; YERCİ, ÖMER; Tıp Fakültesi; Onkoloji Ana Bilim DalıBreast carcinoma is one of the tumors that frequently metastasize to the liver. Extramedullary hematopoiesis (EMH) usually occurs due to insufficient medullary hematopoiesis. In this case report, we present a female patient with sinusoidal breast carcinoma metastasis and extramedullary hematopoiesis in liver biopsy. A 63-year-old female patient with history of breast carcinoma was admitted to our center with respiratory distress. Pleural effusion was detected and thoracentesis was planned. Treatment was given after detection of non-mycobacterial tuberculosis bacillus in the thoracentesis fluid. Antibiotherapy was terminated due to elevation of liver enzymes and bilirubin. The patient's clinical status was evaluated and treatment was re-initiated. The patient did not have any mass lesion in the liver. Tru-cut biopsy was performed to evaluate a possible tuberculosis involvement in the liver. The diagnosis of metastatic breast carcinoma located in the sinusoidal area and cholestatic liver with extramedullary hematopoiesis foci was given using the histomorphological, immunohistochemical and histochemical findings. Radiological evaluation has an important role in staging of malignancies. However, it should be kept in mind that hepatic metastases may present without formation of a mass lesion, and unexpected laboratory results of cases without abnormal radiological features should raise the suspicion of a metastasis. Such materials should be evaluated in detail by making multiple serial sections in the pathology laboratory. Rare metastatic tumor growth patterns not causing a mass lesion such as sinusoidal or portal pattern, should also be kept in mind.Publication The ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans(Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo, 2021-01-01) Tanriverdi, Ozgur; Ozsen, Mine; ÖZŞEN, MİNE; Deligonul, Adem; DELİGÖNÜL, ADEM; Yazici, Serkan; YAZİCİ, SERKAN; Cetintas, Sibel Kahraman; Yalcinkaya, Ulviye; YALÇINKAYA, ÜLVİYE; Sahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Orhan, Sibel Oyucu; OYUCU ORHAN, SİBEL; Ocak, Birol; OCAK, BİROL; Evrensel, Turkkan; EVRENSEL, TÜRKKAN; Kahveci, Ramazan; KAHVECİ, RAMAZAN; Cubukcu, Erdem; ÇUBUKÇU, ERDEM; Tıp Fakültesi; Onkoloji Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-5771-7649; 0000-0002-7846-0870; 0000-0002-0598-7284; 0000-0001-7537-1699; AAJ-8314-2021; AEC-2238-2022; AAM-4927-2020; M-2172-2015Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue sarcoma that originates from the dermis or subcutaneous tissue in the skin. While its prognosis is generally favorable, disease recurrence is relatively frequent. Since morbidity after repeated surgery may be significant, an optimized prediction of recurrence-free survival (RFS) has the potential to improve current management strategies. The purpose of this study was to investigate the prognostic value of the Ki-67 proliferation index with respect to RFS in patients with DFSP We retrospectively analyzed data from 45 patients with DFSP. We calculated the Ki-67 proliferation index as the percentage of immunostained nuclei among the total number of tumor cell nuclei regardless of the intensity of immunostaining. We constructed univariate and multivariate Cox proportional hazards regression models to identify predictors of RFS. Among the 45 patients included in the study, 8 developed local recurrences and 2 had lung metastases (median follow-up: 95.o months; range: 5.2-412.4 months). The RFS rates at 60, 120, and 240 months of follow-up were 83.8%, 76.2%, and 65.3%, respectively. The median Ki-67 proliferation index was 14%. Notably, we identified the Ki-67 proliferation index as the only independent predictor for RFS in multivariate Cox proportional hazards regression analysis (hazard ratio = 1.106, 95% confidence interval = 1.019-1.200, p = 0.016). In summary, our results highlight the potential usefulness of the Ki-67 proliferation index for facilitating the identification of patients with DFSP at a higher risk of developing disease recurrences.Publication Platin-based chemotherapy does not improve survival in patients with non-metastatic resected typical carcinoid tumors(Spandidos Publ Ltd, 2022-10-01) Şahin, Ahmet Bilgehan; Melek, Hüseyin; Ocak, Birol; Oyucu Orhan, Sibel; Erkan, Buket; Caner, Burcu; Deligönül, Adem; Çubukcu, Erdem; Bayram, Ahmet Sami; Akyıldız, Elif Ülker; Evrensel, Türkkan; ŞAHİN, AHMET BİLGEHAN; MELEK, HÜSEYİN; OCAK, BİROL; OYUCU ORHAN, SİBEL; ERKAN ÖZMARASALI, BUKET; CANER, BURCU; DELİGÖNÜL, ADEM; ÇUBUKÇU, ERDEM; BAYRAM, AHMET SAMİ; AKYILDIZ, ELİF ÜLKER; EVRENSEL, TÜRKKAN; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0002-7846-0870; 0000-0003-0684-0900; 0000-0003-1822-8153; 0000-0001-8217-3471; 0000-0003-1591-3323; AAM-4927-2020; AAI-5039-2021; AEC-2238-2022; AAJ-8314-2021; CPN-8681-2022; HJH-6371-2023; ESM-4544-2022; ETP-1691-2022; ABB-7580-2020; ELN-4128-2022; EXZ-0745-2022Chemotherapy is controversial in non-metastatic typical carcinoid (TC) tumors. Therefore, it was aimed to evaluate the impact of platin-based chemotherapy on the survival of patients with lung TC. The medical records of patients who underwent surgical resection for non-metastatic TC from 2002 to 2020 at our institution were retrospectively reviewed. Multivariate regression analysis was performed for chemotherapy and prognostic factors in disease-free survival (DFS) in 72 patients. The pathological stages of patients were as follows: 73.6% of the patients were in stage I, 15.3% in stage II and 11.1% in stage III. A total of 5 patients (6.9%) received platin-based chemotherapy and 6 patients (8.3%) had recurrences. The DFS rates at 12, 36 and 60 months were 98.5, 95.1 and 92.5%, respectively. Log-rank testing showed that patients who received chemotherapy and had stage III disease had shorter DFS (P=0.021 for chemotherapy and P<0.001 for stage). However, multivariate analysis revealed that the pathological stage was the only statistically significant factor affecting DFS (P=0.016). Platin-based chemotherapy did not improve DFS, and the eighth edition of TNM (tumor, nodes, metastases) staging did have prognostic value for patients with non-metastatic TC. Although resection has satisfying long-term outcomes, studies on new agents are needed to decrease the recurrence rate, particularly in patients with stage III disease.Publication Chemo-immunotherapy with atezolizumab in extensive-stage small-cell lung cancer; single-center experience(Akad Doktorlar Yayınevi, 2020-01-01) Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Ocak, Birol; Deligönül, Adem; Kaçan, Turgut; Orhan, Sibel Oyucu; Evrensel, Türkkan; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; OCAK, BİROL; DELİGÖNÜL, ADEM; OYUCU ORHAN, SİBEL; EVRENSEL, TÜRKKAN; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0002-7846-0870; 0000-0001-7537-1699; 0000-0001-8217-3471; 0000-0002-9732-5340; AAJ-8314-2021; AAJ-1027-2021; AAM-4927-2020; ETP-1691-2022; HHA-1866-2022; ESM-4544-2022Chemo-immunotherapy (CIT) with platin, etoposide and monoclonal antibodies targeting the PD-1/PDL-1 pathway has recently improved survival in extensive-stage small-cell lung cancer (SCLC) after decades. We aimed to investigate the efficacy and safety of CIT with atezolizumab in extensive-stage SCLC in chemotherapy naive patients. Eleven patients who were treated and followed in our center were included in this retrospective observational study. All the patients received carboplatin, etoposide and atezolizumab in the induction phase and atezolizumab in the maintenance phase. The Kaplan-Meier test was used to determine progression-free survival (PFS) and overall survival (OS), and the effects of the sites of metastasis were analyzed using the log-rank test. The median age was 69.9 years, and 81.8% were male. The median number of CIT and total atezolizumab cycles was 4 and 7, respectively. 63.6% received maintenance therapy. Median PFS was 5.2 months (95% CI: 3.4-6.9), and median OS was 11.3 months (95% CI: 1.0-21.5). The overall response rate was 63.6%. There was no significant difference between patients with and without liver metastasis in terms of PFS and OS. We observed toxicity higher than grade 2 in more than half of the patients, and hematological toxicities were prominent. CIT with carboplatin, etoposide and atezolizumab is efficient and safe in extensive-stage SCLC considering the PFS, OS, response rates, 12-month survival rate, and side effects. The progression of liver lesions was remarkable. Cranial and thoracic radiation are issues that should be discussed in the future with data from clinical studies.Publication Chemotherapy plus radiotherapy vs . radiotherapy alone in high-risk endometrioid endometrial carcinoma(Verduci Publisher, 2022-01-01) Ocak, B.; Şahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Abakay, Candan Demiröz; DEMİRÖZ ABAKAY, CANDAN; Çubukçu, Erdem; ÇUBUKÇU, ERDEM; Deligönül, Adem; DELİGÖNÜL, ADEM; Caner, Burcu; CANER, BURCU; Evrensel, Türkkan; EVRENSEL, TÜRKKAN; Özerkan, Kemal; ÖZERKAN, KEMAL; DAKİKİ KORUCU, BAHAR; İşlek, G.; Tıp Fakültesi; Onkoloji Ana Bilim Dalı; 0000-0002-7846-0870; 0000-0001-9255-2475; AAM-4927-2020; ABA-2897-2021OBJECTIVE: Adding chemo-therapy to radiotherapy in patients with high-risk endometrioid endometrial cancer (EEC) remains controversial, particularly in stages I-II. We aimed to investigate the effect of treat-ment modalities on survival in high-risk EEC patients. PATIENTS AND METHODS: Patients with high-risk EEC were evaluated retrospectively between 2010 and 2019. Patients who did not re-ceive adjuvant treatment were excluded. We in-cluded seventy patients and formed two groups: patients who received radiotherapy (RT) alone and those who received chemotherapy and ra-diotherapy (CT and RT). RESULTS: The median follow-up time was 60.3 months (8.0-143.5). 38.5% of the patients had relapsed. Recurrence-free survival (RFS) rates were 97. 1%, 68.3% , and 60.8% at 12-, 36-, and 60-month, respectively. Overall survival rates were 97.1%, 80.6%, and 72.6% at 12-, 36-, and 60-month, respectively. Hematological adverse events and neuropathy were more common in the CT and RT group than in the RT group. Multi-variate Cox regression analysis for RFS revealed that the FIGO stage and treatment modalities were statistically independent factors (p=0.031 and p=0.040, respectively). Stage stratified log-rank test revealed that adding chemotherapy im-proved RFS in patients with stage III (p=0.020) but not in stage I-II disease (p=0.725). The num-ber of chemotherapy cycles administered (<= 4 vs. > 4) did not affect survival in all patients and stage III disease (p=0.497, and p=0.436, respec-tively). CONCLUSIONS: Adding chemotherapy to radiotherapy may be considered in high-risk stage III EEC. Further studies are needed to determine the optimal duration of chemother-apy.
- «
- 1 (current)
- 2
- 3
- »